Perspective Therapeutics Reports Disappointing FY Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy CATX?
Source: seekingalpha
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CATX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CATX
Wall Street analysts forecast CATX stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.830
Low
4.00
Averages
11.82
High
18.00
Current: 3.830
Low
4.00
Averages
11.82
High
18.00
About CATX
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
Perspective Therapeutics Prices $175M Public Offering to Advance Clinical Development
- Public Offering Details: Perspective Therapeutics priced an underwritten public offering of 39.6 million common shares at $3.79 each, along with 6.6 million pre-funded warrants at $3.789, aiming for gross proceeds of approximately $175 million, indicating strong market confidence in its future.
- Use of Proceeds: The net proceeds from this offering will be allocated to advancing clinical development, expanding manufacturing capabilities, and supporting working capital and general corporate purposes, while also allowing flexibility for future strategic acquisitions or licensing, highlighting the company's focus on long-term growth.
- Positive Market Reaction: Following the announcement of the public offering, CATX shares rose 11.9% in premarket trading, reflecting investor optimism regarding the company's prospects, which may further enhance its market performance.
- Financial Performance Overview: Although Perspective Therapeutics reported a GAAP EPS of -$0.35, missing expectations by $0.03, its revenue of $0.29 million exceeded forecasts by $0.08 million, demonstrating the company's potential for revenue growth.
See More
Perspective Therapeutics Upgraded to Buy Rating
- Rating Upgrade: Perspective Therapeutics (CATX) has received an upgrade to a 'Buy' rating, indicating analysts' optimistic outlook on its future performance, which may attract more investor interest.
- Price Target Set: The average price target is set at $12.93, reflecting confidence in the company's growth potential, and if achieved, the stock price could see significant upside.
- Market Reaction Anticipation: The upgrade in rating and price target is likely to stimulate a positive market reaction towards CATX, potentially driving the stock price higher and boosting investor confidence.
- Increased Investor Attention: With the improved rating, CATX may attract more institutional investors, further enhancing its market liquidity and shareholder value.
See More
Perspective Therapeutics Reports Disappointing FY Results
- Disappointing Earnings: Perspective Therapeutics reported a FY non-GAAP EPS of -$1.40, missing expectations by $0.20, indicating ongoing challenges in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s revenue of $0.9 million represents a 37.9% year-over-year decrease, falling short of expectations by $0.17 million, reflecting weak market demand that could hinder future growth.
- Decreased Cash Reserves: As of December 31, 2025, cash, cash equivalents, and short-term investments totaled approximately $145 million, down from $227 million in 2024, indicating increased liquidity pressure that may affect future investments and operational capabilities.
- Equity Financing Plan: Perspective Therapeutics announced a $175 million equity offering, which may alleviate short-term funding pressures but could dilute existing shareholders' stakes, impacting shareholder value.
See More
Perspective Therapeutics to Announce Q4 Earnings on March 16
- Earnings Announcement: Perspective Therapeutics is set to release its Q4 earnings on March 16 after market close, with consensus estimates predicting an EPS of -$0.34 and revenue of $0.24 million, providing crucial insights into the company's financial health.
- Equity Offering: The company recently priced a $175 million equity offering, which will support its ongoing research in the SSTR2 solid tumor targeting space, potentially enhancing its market competitiveness and future growth prospects.
- Market Reaction: Following the equity offering announcement, shares of Perspective Therapeutics saw an uptick, indicating increased investor confidence in the company's future, which may set a positive tone for the upcoming earnings report.
- Industry Conference Participation: The company presented at the 44th Annual J.P. Morgan Healthcare Conference, further elevating its visibility among investors and within the industry, showcasing its ongoing efforts and strategic positioning in the tumor targeting treatment sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep
- Clinical Trial Surge: Over 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies being the fastest-growing subsegment, indicating a strong demand for new treatments that could enhance market share for involved companies.
- FDA Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received Fast Track Designation from the FDA based on a 33% response rate in KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than existing therapies, suggesting a faster approval timeline.
- Significant Survival Extension: In clinical trials, patients treated with pelareorep had a median survival of 27 months compared to 11.2 months with standard treatment, indicating a potential market value of $3 billion to $5 billion for this hard-to-treat cancer population.
- Leadership Team Expansion: Oncolytics Biotech recently appointed two executives to support its expanding programs, demonstrating the company's commitment to accelerating product development and enhancing management capabilities for future clinical trials.
See More
Perspective Therapeutics Prices $175M Public Offering to Advance Clinical Development
- Public Offering Details: Perspective Therapeutics priced an underwritten public offering of 39.6 million common shares at $3.79 each, along with 6.6 million pre-funded warrants at $3.789, aiming for gross proceeds of approximately $175 million, indicating strong market confidence in its future.
- Use of Proceeds: The net proceeds from this offering will be allocated to advancing clinical development, expanding manufacturing capabilities, and supporting working capital and general corporate purposes, while also allowing flexibility for future strategic acquisitions or licensing, highlighting the company's focus on long-term growth.
- Positive Market Reaction: Following the announcement of the public offering, CATX shares rose 11.9% in premarket trading, reflecting investor optimism regarding the company's prospects, which may further enhance its market performance.
- Financial Performance Overview: Although Perspective Therapeutics reported a GAAP EPS of -$0.35, missing expectations by $0.03, its revenue of $0.29 million exceeded forecasts by $0.08 million, demonstrating the company's potential for revenue growth.
See More
